The Event is Live Today

Access the Event
April 23-25, 2024

The CRISPR Medicine Conference

Important Dates for the CRISPR Medicine Conference 2024

Before the Event:

  • September 1st, 2023: Registration & abstract submissions open
  • January 12th, 2024: Early bird registration deadline (EXTENDED to January 19th)
  • January 24th, 2024: Abstract submission deadline (EXTENDED to January 31st)
  • February 29th, 2024: Oral and poster notifications & final programme available
  • March 1st, 2024: Travel grant notification
  • April 8th, 2024: Registration deadline in-person event (EXTRA Tickets available)
  • April 21st, 2024: Registration deadline virtual event
  • April 22nd, 2024: Abstract publication in the CRISPR Medicine News portal


  • April 22nd, 2024: Virtual event
  • April 23-25th, 2024: In-person event in Copenhagen, Denmark

View the Final CRISPRMED24 Program here

Access the CRISPRMED24 Live App here

First version of the Abstract Book is now available


The first CRISPR Medicine Conference will take place in Copenhagen, Denmark, on the 23-25th April 2024 (virtual event 22nd April). This event will bring European CRISPR research to the forefront, with 6 main tracks that cover the most important topics in the therapeutic gene-editing field: Tools, Delivery, Safety, Functional Genomics, Standards and Regulations, Pre-clinical Research and Clinical Trials.

This will be a hybrid event with a strong focus on in-person attendance and on-demand virtual content. The conference will include talks by reputable speakers from academia and industry, as well as several workshops focused on developing useful skills for a successful career in gene editing.

You can register to attend the event and submit an abstract directly through this website. Our separate in-person and virtual poster sessions will allow any type of attendee to present and discuss their research with their peers. The top-scoring abstracts will be presented as oral presentations and the authors will be interviewed by CRISPR Medicine News, which boasts an audience of over 25,000 readers per month.

Once you have registered, you will be able to explore the content and see the list of participants.

Meet the confirmed CRISPRMED24 attendees here.

If you have any questions, please refer to our FAQ section or contact CRISPRMED24 staff at

**CRISPRMED24 Newsletter - Sign up here**

If you can not attend this year, reserve already the dates for the 2nd CRISPR Medicine Conference, CRISPRMED25 - Stay updated here.

Abstract review panel:

  • Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
  • Toni Cathomen, Prof. and Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
  • Alessia Cavazza, Ass. Prof., Group Leader, University College London Great Ormond Street Institute of Child Health, England
  • Anna Cereseto, Prof. and Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
  • Ayal Hendel, Principal Investigator at The Mina and Everard Goodman Faculty of Life Sciences at Bar-Ilan University, Israel
  • Jan Gorodkin, Professor and Group Leader at the University of Copenhagen, Denmark
  • Marianne Carlon, Ass. Prof. at the Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) and the Center for Molecular Medicine of the KU Leuven Faculty of Medicine, Belgium
  • Paula Rio, Head of the Bone Marrow Failure Unit at CIEMAT/CIBERER/IIS-FJD at the Universidad Autónoma in Madrid, Spain
  • Pia Johansson, Scientific Coordinator of the Cell and Gene Therapy Core at Lund University, Sweden

Keynote Speaker

  • Luigi Naldini

    Luigi Naldini

    San Raffaele Telethon Institute for Gene Therapy and San Raffaele University, Milan, Italy

    Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy).

    For the past 25 years he has pioneered the development and application of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also yielded novel insights into haematopoietic stem cell function, induction of immunological tolerance, and tumour angiogenesis.

    Professor Naldini's work has also contributed to advancing the use of artificial nucleases for targeted genome editing in cell- and gene therapy. To date, he has published over 290 scientific papers, and his SCOPUS Author h-index is 105. He is also co-founder of three innovative biotech start-up companies: Genenta (recently listed on Nasdaq), Epsilen Bio (now acquired by Chroma Medicine) and Genespire.

    Google Scholar ORCIID Lab Webpage


  • Ampliqon
  • AstraZeneca
  • baSeq
  • Bayer
  • Benchling
  • BioSpring
  • Broken String Biosciences
  • CasCure
  • Cellecta
  • ChemoMetec
  • Clean Cells
  • CountaGen
  • EW Lab
  • Frontiers
  • Full Circle Therapeutics
  • GenScript
  • IDT
  • iotaSciences
  • MaxCyte
  • Mission Bio
  • Moligo Technologies
  • OMNI Life Science
  • RadaHeim
  • Samplix
  • SciLife Lab
  • ST Pharm
  • Synthego
  • VectorBuilder
  • Vivlion
  • VUS Diagnostics
  • ZeClinics

Confirmed Speakers

Scientific Committee

· Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
· Toni Cathomen, Prof. and Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
· Alessia Cavazza, Ass. Prof., Group Leader, University College London Greater Ormond Street Institute of Child Health, England
· Anna Cereseto, Prof. and Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy at University of Trento, Italy
· Karen O´Hanlon Cohrt, Chief Editor CMN

Organising Committee

· Karen O´Hanlon Cohrt, Chief Editor, CRISPR Medicine News
· Gorm Palmgren, Science Writer and Editor, CRISPR Medicine News
· Jens-Ole Bock, Founder, CRISPR Medicine News
· Antonio Carusillo, Science Writer, CRISPR Medicine News
· Manel Lladó, Science Writer, CRISPR Medicine News

Attending Institutions and Companies

  • Aalborg University Hospital
  • Akershus University Hospital
  • Akribion Genomics
  • Aldevron
  • Alia Therapeutics
  • Altos Labs
  • Amgen
  • Amsterdam University Medical Center
  • Ankara University
  • Ariya Bio
  • AstraZeneca
  • Basceamp Research
  • Bar-Ilan, Israel
  • Bayer
  • Boston Children's Hospital
  • Broken String Biosciences
  • Bursa Uludag University
  • Cambridge University
  • Cancer Research Horizons
  • Cardiff University
  • Cascure
  • Caszyme
  • Cellecta
  • Cellectis
  • Center for Applied Medical Research - University of Navarra
  • Central Committee on Research Involving Human Subjects
  • Centro de Investigaciones Medioambientales y Technológicas
  • Charité Universitätsmedizin Berlin
  • Chroma Medicine
  • CHU Sainte Justine
  • Chung Ang University
  • Danish Medicines Agency
  • Defence Science and Technology Laboratory
  • Ege University Hospital
  • Eligo Bioscience
  • EMBL
  • Ensoma
  • ETH Zurich
  • Excision BioTherapeutics
  • Full Circles Therapeutics
  • German Sport University Cologne
  • Ghent University
  • Goethe University, Frankfurt
  • GSK
  • Hacettepe University Depart of Stem Cell Sciences
  • Hamad Bin Khalifa University
  • Harvard Medical School
  • Hospital for Sick Children Toronto
  • Huntington's Disease Society of America
  • Imagine Institute
  • IMBA - Institute of Molecular Biology of the Austrian Academy of Sciences
  • IMP- Institute of Molecular Pathology
  • Institut de la Vision Paris
  • Instituto de Biologia Experimental e Tecnológica
  • Integra Therapeutics
  • Intellia Therapeutics
  • Ionis Pharmaceuticals
  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
  • I-Stem
  • Jamia Millia Islamia
  • John Hopkins University Applied Physics Laboratory
  • Karolinska Institute, Sweden
  • Leiden University
  • Life Edit Therapeutics
  • Lonza
  • Lund University, Sweden
  • Masaryk University
  • Max Delbeck Center for Molecular Medicine
  • Max Planck Institute for Biology of Ageing
  • Metagenomi
  • Miltenyi Biotec
  • MissionBio
  • Myllia Biotechnology
  • MyoPax
  • National Center for Cancer Immune Therapy Denmark
  • National Institute of Standards & Technology (NIST), US
  • Northwestern University
  • Novartis
  • Novo Nordisk
  • PixelBiosciences
  • Quantum Sky
  • Recode Therapeutics
  • Salk Institute
  • San Raffaele - Telethon Institute for Gene Therapy (SR-Tiget), Italy
  • Saudi Food and Drug Authority
  • Second Faculty of Medicine - Charles University
  • SNIPR Biome
  • Sparing Vision
  • Technical University of Denmark
  • Technical University of Munich/IMPRS-ML
  • Tehran University of Medical Sciences
  • Teknologiens Mediehus
  • Tessera Therapeutics
  • The Jackson Laboratory
  • The McDonnell Genome Institute
  • Thermo Fisher Scientific
  • The Swedish gene Technology Advisory Board/Swedish Research Council (VR)
  • T-knife Therapeutics
  • ToolGen
  • Tübingen University Hospital
  • Universidad Autónoma de Madrid, Spain
  • UCL, England
  • Ulsan National Institute of Science and Technology
  • Uni Klinik Freiburg, Germany
  • University Clinic Münster
  • University of Aarhus, Denmark
  • University of Adelaide
  • University of Auckland
  • University of Bern
  • University of Birmingham
  • University of Bologna
  • University of Bordeaux
  • University of Bristol
  • University of Copenhagen, Denmark
  • University of Helsinki
  • University of Lagos
  • University of Manchester
  • University of Melbourne
  • University of Modena and Reggio Emilia
  • University of Oslo
  • University of Pennsilvania
  • University of Trento, Italy
  • University of Vienna
  • University of Zürich
  • Valinor
  • Vertex Pharmaceuticals
  • Verve Therapeutics
  • Vilnius University Life Sciences Center
  • Vita-Salute San Raffaele University, Italy
  • Washington University in St. Louis
  • Whitehead Institue
  • ZeClinics

Attendees (confimed) - Investors

  • Eir Ventures
  • Lundbeck Foundation
  • Mercator Investment Management
  • Peraton


Copenhagen, Denmark

Registration period

August 1, 2023 - 00:00 until April 25, 2024 - 10:00

Submission period

August 1, 2023 - 12:00 until April 25, 2024 - 12:00

Contact us

If you have any questions, please contact .